Giacomo Allegrini
University of Pisa(IT)Ospedale di Livorno(IT)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Gastric Cancer Management and Outcomes, Hepatocellular Carcinoma Treatment and Prognosis, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest(2007)1,229 cited
- → FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study(2015)1,081 cited
- → Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer(2014)1,066 cited
- → Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer(2021)702 cited
- → Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial(2020)314 cited